Our top pick for
Building a portfolio
ContraFect Corporation is a biotechnology business based in the US. ContraFect Corporation shares (CFRX) are listed on the NASDAQ and all prices are listed in US Dollars. ContraFect Corporation employs 24 staff and has a market cap (total outstanding shares value) of USD$149.3 million.
|Latest market close||USD$5.34|
|52-week range||USD$4.45 - USD$13.399|
|50-day moving average||USD$5.4638|
|200-day moving average||USD$5.6578|
|Wall St. target price||USD$17.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.44|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-14)||2.89%|
|1 month (2020-12-22)||0.75%|
|3 months (2020-10-21)||5.34|
|6 months (2020-07-21)||-17.59%|
|1 year (2020-01-21)||376.79%|
|2 years (2019-01-18)||874.45%|
|3 years (2018-01-19)||376.79%|
|5 years (2016-01-21)||45.54%|
Valuing ContraFect Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ContraFect Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ContraFect Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, ContraFect Corporation shares trade at around 19x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$-1,698,063|
|Return on assets TTM||-48.44%|
|Return on equity TTM||-283.93%|
|Market capitalisation||USD$149.3 million|
TTM: trailing 12 months
There are currently 1.7 million ContraFect Corporation shares held short by investors – that's known as ContraFect Corporation's "short interest". This figure is 11.2% up from 1.5 million last month.
There are a few different ways that this level of interest in shorting ContraFect Corporation shares can be evaluated.
ContraFect Corporation's "short interest ratio" (SIR) is the quantity of ContraFect Corporation shares currently shorted divided by the average quantity of ContraFect Corporation shares traded daily (recently around 250977.87610619). ContraFect Corporation's SIR currently stands at 6.78. In other words for every 100,000 ContraFect Corporation shares traded daily on the market, roughly 6780 shares are currently held short.
However ContraFect Corporation's short interest can also be evaluated against the total number of ContraFect Corporation shares, or, against the total number of tradable ContraFect Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ContraFect Corporation's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 ContraFect Corporation shares in existence, roughly 60 shares are currently held short) or 0.0691% of the tradable shares (for every 100,000 tradable ContraFect Corporation shares, roughly 69 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ContraFect Corporation.
Find out more about how you can short ContraFect Corporation stock.
We're not expecting ContraFect Corporation to pay a dividend over the next 12 months.
ContraFect Corporation's shares were split on a 1:10 basis on 4 February 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ContraFect Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for ContraFect Corporation shares which in turn could have impacted ContraFect Corporation's share price.
Over the last 12 months, ContraFect Corporation's shares have ranged in value from as little as $4.45 up to $13.399. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ContraFect Corporation's is 1.0882. This would suggest that ContraFect Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. ContraFect Corporation has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. The company also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Everything we know about the NLS Pharmaceutics Ltd IPO, plus information on how to buy in.
Everything we know about the GitLab IPO, plus information on how to buy in.
Everything we know about the Longeveron LLC IPO, plus information on how to buy in.
Everything we know about the Signify Health Inc IPO, plus information on how to buy in.
Everything we know about the Biophytis SA IPO, plus information on how to buy in.
Everything we know about the NexImmune Inc IPO, plus information on how to buy in.
Everything we know about the Adagene Inc IPO, plus information on how to buy in.
Everything we know about the Cloopen Group Holding Limited IPO, plus information on how to buy in.
Everything we know about the Decipher Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Proterra IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.